Patients
-
News
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed yesterday evening. The pharmaceutical giant was unclear if the patient…
Read More » -
News
Hidden Victims Of The Pandemic: Blood Bank Stocks Run Low As India’s Healthcare System Buckles
As public healthcare resources are redirected to halt the spread of coronavirus, victims of other life-threatening diseases pay the ultimate price. This recent news story, published by The Telegraph, depicts…
Read More » -
News
-
News
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
Fulcrum Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that FTX-6058, its investigational treatment for sickle cell disease (SCD) and…
Read More » -
News
TIF Develops Mobile Application To Support Patients With Thalassaemia
As part of its enduring efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF will soon introduce a novel mobile health application, named ‘’THALIA Mobile…
Read More » -
News
Coming Up This Week: ”Iron Monitoring in Thalassaemia” Webinar for Patients
Although chronic blood transfusion regimens have added decades to the lives of patients with thalassaemia, clinicians are now faced with increasingly complicated management challenges. The devastating effect of the accumulated…
Read More » -
News
Gene Therapy LentiGlobin Granted Priority Medicines Designation for Sickle Cell Disease in the EU
Bluebird Bio’s investigational gene therapy LentiGlobin has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of sickle cell disease (SCD). Given to candidate therapies with promising clinical data for diseases of high…
Read More » -
Thal e-Course Webinars
THAL e-COURSE: Liver Disease in Thalassaemia by Prof. John Koskinas
Meeting your continuing educational needs on thalassaemia has never been easier! The 1st Webinar to inaugurate the TIF Thal e-Course Webinar Series for patients with thalassaemia has been successfully completed.…
Read More » -
News
Health Canada Approves REBLOZYL® For Adult Patients with β-Thalassaemia
Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL® (luspatercept) for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia…
Read More » -
News
TIF Takes Active Part At The IAPO 9th Global Patients Congress
The International Alliance of Patients’ Organizations (IAPO) conducted online the 9th Global Patients Congress #GPC2020 on 16-17 September 2020, under the theme ”Co-creation of Innovative Healthcare”. The Congress featured a…
Read More »